Bone Biologics (BBLGW) Current Assets (2013 - 2026)

Bone Biologics (BBLGW) has reported Current Assets for 13 consecutive years, with $4.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 36.64% year-over-year to $4.4 million in Q2 2026; TTM through Jun 2026 was $4.4 million, a 36.64% decrease from a year earlier, with the FY2025 full-year figure at $5.8 million, up 50.11% from the prior year.
• Current Assets was $4.4 million for Q2 2026 at Bone Biologics, down from $5.8 million in the prior quarter.
• Over five years, Current Assets peaked at $8.5 million in Q4 2022 and troughed at $3.2 million in Q1 2025.
• A 5-year average of $4.9 million and a median of $4.1 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slumped 56.0% in 2023 and soared 119.27% in 2025, its largest moves.
• Over 5 years, Current Assets stood at $8.5 million in 2022, then tumbled by 56.0% to $3.7 million in 2023, then increased by 3.31% to $3.9 million in 2024, then surged by 50.11% to $5.8 million in 2025, then retreated by 23.45% to $4.4 million in 2026.
• The last three Current Assets figures came in at $4.4 million (Q2 2026), $5.8 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.